Study Objectives and Assessments:

• Comet-1: Evaluate the safety and efficacy of two doses of topical ophthalmic AR-15512
  compared with vehicle in subjects with DED (Phase 2b)

   

• Comet-2&3: Evaluate the safety and efficacy of topical ophthalmic AR-15512 0.003% compared
  with its vehicle administered BID in subjects with DED

   

• Comet-4: A long-term safety study evaluating the safety and systemic exposure of AR-15512
  compared with vehicle administered BID in subjects with DED